Los mejores médicos para el tratamiento de Linfoma no Hodgkin en el extranjero — Página 3

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

El profesor Bosch es un líder de renombre mundial en leucemia linfocítica crónica (LLC) y trastornos linfoproliferativos, pionero en nuevos tratamientos y tecnologías.

• Jefe de Hematología en el Instituto de Oncología IOB desde 2004
• Ha publicado más de 100 artículos en revistas de primer nivel como The New England Journal of Medicine
• Actualmente participa en más de 80 ensayos clínicos de fase 1 a 3
• Presidente del Grupo Español de Leucemia Linfocítica Crónica (GELLC)

Especializado exclusivamente en hematología con enfoque en el tratamiento de linfomas. Ejerce en el Rambam Medical Center, un hospital israelí de primer nivel.

• Ofrece un enfoque dedicado a la atención compleja que requieren los linfomas
• Posee un conocimiento profundo de los tratamientos y protocolos específicos para linfomas
• Su especialización en hematología garantiza una atención actualizada para los cánceres de la sangre

La profesora Zila Zuckerman se especializa en hematología y trasplantología en el Centro Médico Rambam.

• Experiencia en el tratamiento del linfoma no Hodgkin
• Especializada en hematología y trasplantología
• Trabaja en el Centro Médico Rambam

Reconocido por Forbes como uno de los mejores médicos en 2018, el Dr. Stepensky ha realizado más de 3500 trasplantes de médula ósea en el Centro Médico Hadassah.

• _doctor_3609_años_ de experiencia en hematología pediátrica
• Especializado en el tratamiento de niños con cánceres de sangre raros
• Conocido entre los pacientes como 'el que trasplanta vida'
• Trabaja en el Centro Médico Hadassah, un hospital israelí líder

Ofer Spielberg es un oncólogo especializado en linfoma no Hodgkin en el Centro Médico Assuta.

• Se centra en métodos de diagnóstico avanzados y protocolos de tratamiento personalizados
• Integra las últimas investigaciones clínicas en la práctica quirúrgica
• Disponible para asesorar tanto en casos de linfoma rutinarios como complejos

La Prof. Elke Jaeger es una destacada oncóloga alemana especializada en linfoma no Hodgkin, reconocida por el ranking Focus.

• Más de 35 años de experiencia en oncología y hematología
• Jefa de Oncología y Hematología en la Clínica Nordwest
• Especializada en sarcomas y casos complejos de linfoma
• Reconocida como una de las mejores oncólogas de Alemania

Director de la Unidad de Linfomas en San Raffaele – El Dr. Ferreri fundó la Fundación Italiana de Linfomas para avanzar en el tratamiento de los linfomas.

• Subdirector de Hematología y Oncología con más de 28 años de experiencia
• Autor de más de 300 artículos de investigación sobre el tratamiento de linfomas
• Miembro de las principales asociaciones de hematología y oncología del mundo
• Especializado en linfomas no Hodgkin con un enfoque de investigación dedicado

El profesor asociado Rafet Eren se especializa en hematología y cuenta con casi 50 publicaciones en revistas nacionales e internacionales.

• Miembro de la Sociedad Europea de Hematología y de la Asociación Turca de Hematología
• Ganador del premio al Joven Investigador en el 42º Congreso Nacional de Hematología
• Habla inglés con fluidez
• Trabaja en el Hospital Universitario Biruni

Con más de _doctor_6792_años_ de especialización en hematología y oncología pediátrica, el Dr. Apak ha tratado numerosos casos complejos de linfoma en el Hospital Universitario Biruni.

• Dirige la División de Hematología y Oncología Pediátrica en Cerrahpaşa
• Especializado en terapia de células T CAR y tratamientos avanzados de leucemia
• Autor de 75 publicaciones internacionales sobre cáncer infantil
• Editor asistente de la revista Turkish Pediatrics Archives

El Dr. Eckhart Weidmann dirige el sector de Hematología en la Clínica Nordwest, especializado en tratamientos de trastornos sanguíneos con 36 años de práctica.

• Experto en el tratamiento del linfoma no Hodgkin
• Profesor con una amplia trayectoria académica y clínica
• Se centra en los trastornos sanguíneos en una clínica de hematología líder

Jefe de Hematología y Trasplante de Médula Ósea en San Raffaele – El profesor Ciceri dirige ensayos de terapia celular y génica para cánceres de la sangre.

• Investigador principal en ensayos clínicos para cánceres hematológicos
• Publicó más de 180 artículos científicos sobre hematología y trasplantes
• Miembro de la Asociación Europea de Hematología y otras sociedades clave
• Especialista en hematología con amplia experiencia en trasplante de médula ósea

El Prof. Baytan se especializa en cánceres infantiles, incluido el linfoma no Hodgkin, con más de 34 años de experiencia en hematología y oncología pediátrica.

• Ha publicado 15 artículos en revistas internacionales arbitradas
• Especializado en tratamientos de leucemia y linfoma
• Autor de 3 libros o capítulos de libros en idiomas locales y extranjeros
• Profesor asistente de hematología pediátrica en la Universidad de Uludağ

El Prof. Dr. Serdar Bedii Omay ha publicado más de 65 artículos científicos sobre hematología y trasplante de médula ósea. Se formó en la Facultad de Medicina de Mie en Japón.

• Especializado en hematología con más de _doctor_2835_años_ de experiencia
• Profesor en la Universidad del Egeo y la Universidad Técnica de Karadeniz
• Experto en hematología molecular
• Trabajó en instituciones prestigiosas, incluida la Facultad de Medicina de Hacettepe